INVIVYD INC.
NASDAQ: IVVD (Invivyd, Inc.)
Kemas kini terakhir: 3 jam lalu0.822
0.01 (0.69%)
| Penutupan Terdahulu | 0.817 |
| Jumlah Dagangan | 7,129,025 |
| Harga / Pendapatan (P/E Ke hadapan) | 44.64 |
| Harga / Jualan (P/S) | 4.26 |
| Harga / Buku (P/B) | 1.50 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -149.70% |
| EPS Cair (TTM) | -1.19 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.65% |
| Nisbah Semasa (MRQ) | 1.53 |
| Aliran Tunai Operasi (OCF TTM) | -141.41 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -65.66 M |
| Pulangan Atas Aset (ROA TTM) | -57.84% |
| Pulangan Atas Ekuiti (ROE TTM) | -122.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Invivyd, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.50 |
|
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 41.18% |
| % Dimiliki oleh Institusi | 66.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bvf Inc/Il | 30 Jun 2026 | 28,165,000 |
| Maverick Capital Ltd | 30 Jun 2026 | 18,970,913 |
| Perceptive Advisors Llc | 30 Jun 2026 | 18,490,636 |
| M28 Capital Management Lp | 30 Jun 2026 | 9,248,250 |
| Saturn V Capital Management Lp | 30 Jun 2026 | 8,392,288 |
| Soleus Capital Management, L.P. | 30 Jun 2026 | 7,708,727 |
| Siren, L.L.C. | 30 Jun 2026 | 5,000,000 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |